Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PFE (Pfizer) How high will it go? -- Ignore unavailable to you. Want to Upgrade?

To: Mick Mørmøny who wrote (7579)	5/3/1999 6:52:00 AM
From: BigKNY3	Read Replies (2) \| Respond to of 9523

Monsanto Subsidiary to Begin Television Ads for Arthritis Painkiller May 3, 1999 St. Louis Post-Dispatch, Missouri via NewsEdge Corporation : May 1-- Sales of Celebrex, now the fastest-selling new prescription drug, should get another boost starting Wednesday. G.D. Searle & Co. is launching a television advertising campaign aimed at arthritis sufferers. The Celebrex ad created by Leo Burnett Co. premieres in prime time when CBS presents "The 34th Academy of Country Music Awards." Joseph Papa, president of U.S. operations for Searle, said the television campaign is being launched now because May is arthritis education month. The consumer campaign will be ongoing. In an interview Friday, Papa declined to disclose the budget for Celebrex consumer advertising. He said Searle will spend the most of its promotional dollar educating physicians, pharmacists and other medical professionals about the benefits of Celebrex, a Cox-2 inhibitor that reduces pain and inflammation caused by rheumatoid and osteoarthritis. In the past, prescription drug makers concentrated on promoting their products to medical professions. Direct to consumer advertising is a relatively recent tactic, one that Searle has used with some success in marketing its leading prescription sleep aid, Ambien. Searle, a subsidiary of Monsanto, began selling Celebrex in February. -----